{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=78",
    "query": {
      "intervention": "0.9% Sodium Chloride (NaCl)",
      "page": 78
    },
    "page_size": 10
  },
  "pagination": {
    "page": 78,
    "page_size": 10,
    "total_count": 1988,
    "total_pages": 199,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=79&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+%28NaCl%29&page=77&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T07:06:34.972Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04606602",
      "title": "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperlipidemias",
        "Dyslipidemias",
        "Elevated Lp(a)"
      ],
      "interventions": [
        {
          "name": "SLN360",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Silence Therapeutics plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2020-11-18",
      "completion_date": "2023-08-23",
      "has_results": false,
      "last_update_posted_date": "2024-08-12",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04606602"
    },
    {
      "nct_id": "NCT03303677",
      "title": "Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Rhinosinusitis (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "Saline Nasal",
          "type": "DRUG"
        },
        {
          "name": "Budesonide Nasal",
          "type": "DRUG"
        },
        {
          "name": "Topical Antibacterial (Product)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-04-01",
      "completion_date": "2019-11-01",
      "has_results": false,
      "last_update_posted_date": "2018-03-30",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03303677"
    },
    {
      "nct_id": "NCT04824365",
      "title": "Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Sodium Pyruvate",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cellular Sciences, inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-04-12",
      "completion_date": "2022-08-12",
      "has_results": true,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 2,
      "location_summary": "Virginia Gardens, Florida • Springfield, Missouri",
      "locations": [
        {
          "city": "Virginia Gardens",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04824365"
    },
    {
      "nct_id": "NCT05952934",
      "title": "Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "interventions": [
        {
          "name": "0.5 mL Candin®/injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 100,
      "start_date": "2024-02-12",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 6,
      "location_summary": "Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05952934"
    },
    {
      "nct_id": "NCT03848845",
      "title": "Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "belantamab mafodotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2019-03-14",
      "completion_date": "2023-06-14",
      "has_results": true,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Indianapolis, Indiana • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848845"
    },
    {
      "nct_id": "NCT05330975",
      "title": "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Afluria® Quadrivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1273.214",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3317,
      "start_date": "2022-04-01",
      "completion_date": "2024-11-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-30",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330975"
    },
    {
      "nct_id": "NCT04331002",
      "title": "Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tibial Meniscus Injuries",
        "Tibial Meniscus Tears",
        "Tibial Meniscus, Torn",
        "Anterior Cruciate Ligament Tear"
      ],
      "interventions": [
        {
          "name": "Zilretta",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Austin V Stone",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 1,
      "start_date": "2020-08-21",
      "completion_date": "2022-07-11",
      "has_results": true,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04331002"
    },
    {
      "nct_id": "NCT01594437",
      "title": "Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "TCN-202",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Theraclone Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-05",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-21",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01594437"
    },
    {
      "nct_id": "NCT02377466",
      "title": "A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obstetric Labour, Premature"
      ],
      "interventions": [
        {
          "name": "Retosiban IV infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 45 Years · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2016-02-29",
      "completion_date": "2017-07-24",
      "has_results": true,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02377466"
    },
    {
      "nct_id": "NCT07223229",
      "title": "Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-segmental Vitiligo"
      ],
      "interventions": [
        {
          "name": "EI-001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Elixiron Immunotherapeutics (Hong Kong) Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2025-12-30",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-11-02T07:06:34.972Z",
      "location_count": 5,
      "location_summary": "Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Mayfield Heights",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223229"
    }
  ]
}